Miguel Rosado

Prof. Miguel Rosado

Centre for Neuroscience and Cell Biology
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ISInês Serrenho
Inês Serrenho
Miguel RosadoMiguel Rosado
Miguel Rosado
ADAlexandra Dinis
Alexandra Dinis
CCCarla Cardoso
Carla Cardoso
Mário GrãosMário Grãos
Mário Grãos
GBGraça Baltazar
Graça Baltazar
Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of mortality and morbidity in the perinatal period. This condition results from a period of ischemia and hypoxia to the brain of neonates, leading to several disorders that profoundly affect the daily life of patients and their families. Currently, therapeutic hypothermia (TH) is the standard of care in developing countries; however, TH is not always effective, especially in severe cases of HIE. Addressing this concern, several preclinical studies assessed the potential of stem cell therapy (SCT) for HIE. With this systematic review, we gathered information included in 58 preclinical studies from the last decade, focusing on the ones using stem cells isolated from the umbilical cord blood, umbilical cord tissue, placenta, and bone marrow. Outstandingly, about 80% of these studies reported a significant improvement of cognitive and/or sensorimotor function, as well as decreased brain damage. These results show the potential of SCT for HIE and the possibility of this therapy, in combination with TH, becoming the next therapeutic approach for HIE. Nonetheless, few preclinical studies assessed the combination of TH and SCT for HIE, and the existent studies show some contradictory results, revealing the need to further explore this line of research.

1 January 2019
Verified
Book Chapter
Closed access
Miguel RosadoMiguel Rosado
Miguel Rosado
RSRafael Silva
Rafael Silva
MBMariana G Bexiga
Mariana G Bexiga
JJJohn G Jones
John G Jones
Bruno ManadasBruno Manadas
Bruno Manadas
Sandra AnjoSandra Anjo
Sandra Anjo

22 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Miguel RosadoMiguel Rosado
Miguel Rosado
CECatarina Empadinhas
Catarina Empadinhas
VSVitor Santos
Vitor Santos
CSCátia Santa
Cátia Santa
MGMário Grãos
Mário Grãos
Bruno ManadasBruno Manadas
Bruno Manadas
Background: Early detection of individuals at risk for clinical deterioration in first-episode psychosis (FEP) remains a vital challenge in psychiatric care. Emerging evidence indicates that immune dysregulation might play a crucial role in the pathophysiology and progression of psychotic disorders. Aims: This study examined the predictive potential of a plasma cytokine and chemokine panel in anticipating clinical stage transition of FEP patients. Method: Using multiplex immunoassays, plasma samples from a cohort of 35 FEP patients were screened for the quantification of 21 analytes. Participants were clinically assessed at baseline and follow-up and classified according to a validated staging model. Data was used to predict clinical stability over a 12-month follow-up period. Results: IL-17A was found to be significantly increased in transitioning patients (p = 0.045), with a medium standardized effect size and wide confidence interval (Hedges’ g = - 0.687, 95% CI [-1.379, 0.004]). A logistic regression model was determined, which revealed that higher baseline levels of IL-17A were significantly linked to progression to a more advanced clinical stage, while higher baseline levels of MIP-3α and IFN-γ were associated with clinical stability. This combined cytokine model exhibited strong predictive capacity (AUC = 0.853), indicating its potential as a biomarker panel for early risk assessment. Conclusions: These findings highlight the importance of neuroimmune mechanisms in the development of psychotic disorders and advocate for the inclusion of immunological markers within staging-based models of care. Incorporating cytokine profiling into clinical practice could improve personalised treatment strategies and lead to better long-term outcomes for individuals with FEP.

2 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Sandra AnjoSandra Anjo
Sandra Anjo
Miguel RosadoMiguel Rosado
Miguel Rosado
IBInês Baldeiras
Inês Baldeiras
AGAndreia Gomes
Andreia Gomes
DPDiana Pires
Diana Pires
Bruno ManadasBruno Manadas
Bruno Manadas
Neurodegenerative Diseases (NDs) present a significant health challenge. Therefore, finding reliable blood biomarkers for these diseases has been of pivotal importance in translational/clinical research. However, conventional omics struggle with the complexity of blood samples, which makes it difficult to achieve the desired goal. To address this, the potential of High Molecular Weight (HMW) serum fractionation under non-denaturing conditions as a complementary approach to the direct analysis of whole serum proteomics was explored in this work. To achieve this, a total of 58 serum samples of Alzheimer's disease (AD), Parkinson's disease (PD) patients and control individuals underwent two strategies: i) direct analysis of whole serum and ii) non-denaturing fractionation using 300 kDa cut-off filters (HMW serum). As expected, each approach was able to capture different sets of differentially regulated proteins since most of the altered proteins were not shared between them. More importantly, it was possible to create a discriminant model using the altered proteins from both datasets capable of distinguishing the three groups (AUC = 0.999 and, median sensitivity and specificity of 97.4% and 91.7%, respectively). Altogether, this work demonstrated that HMW fractionation can be a valuable complementary method to direct serum analysis and could enhance biomarker discovery. The 10 proteins included in the model (5 from each strategy), comprise clear evidence for the contribution of apolipoproteins for the diagnosis of NDs, revealing potential changes within lipid metabolism and the organization of macromolecules and their complexes, thereby uncovering effects that remain hidden from a conventional serum proteome analysis.

24 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Sandra AnjoSandra Anjo
Sandra Anjo
Miguel RosadoMiguel Rosado
Miguel Rosado
IBInês Baldeiras
Inês Baldeiras
AGAndreia Gomes
Andreia Gomes
DPDiana Pires
Diana Pires
Bruno ManadasBruno Manadas
Bruno Manadas
Identification of reliable blood biomarkers for neurodegenerative diseases (NDs) is crucial for translational and clinical research. However, conventional omics struggle with blood samples complexity, hindering desired outcomes. In this work the potential of High Molecular Weight (HMW) fractionation under non-denaturing conditions as a complementary approach to the conventional proteomics for identifying serum biomarkers in NDs was explored. A cohort of 58 serum samples of Alzheimer’s disease (AD), Parkinson’s disease (PD) patients and control (CT) individuals was used to compare the two proteomics strategies: i) direct analysis of whole serum and ii) non-denaturing fractionation using 300 kDa cut-off filters (HMW serum). Although both approaches quantified a similar set of proteins, each approach captured a distinct subset of differentially altered proteins, suggesting that HMW fractionation identified additional types of alterations beyond conventional protein level changes. A discriminant model combining altered proteins from both datasets effectively distinguished between the three groups (AUC = 0.999 and median sensitivity and specificity of 97.4% and 91.7%, respectively). Importantly, this performance surpassed that of any model created using each method individually. Altogether, this work demonstrated that HMW fractionation can be a valuable complementary method to direct serum analysis and could enhance biomarker discovery. The 10 proteins included in the model (5 from each strategy), comprise clear evidence for the contribution of apolipoproteins for the diagnosis of NDs, revealing potential changes within lipid metabolism and the organization of macromolecules and their complexes, thereby uncovering effects that remain hidden from a conventional serum proteome analysis.

25 August 2026 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
Miguel RosadoMiguel Rosado
Miguel Rosado
CECatarina Morais Empadinhas
Catarina Morais Empadinhas
VSVitor Santos
Vitor Santos
CSCátia Santa
Cátia Santa
MGMário Grãos
Mário Grãos
Bruno ManadasBruno Manadas
Bruno Manadas
Early detection of individuals at risk for clinical deterioration in first-episode psychosis (FEP) remains a vital challenge in psychiatric care. Emerging evidence indicates that immune dysregulation might play a crucial role in the pathophysiology and progression of psychotic disorders. This study examined associations between a plasma cytokine and chemokine panel and clinical stage transition in FEP patients. Using multiplex immunoassays, plasma samples from a small cohort of 35 FEP patients were screened for the quantification of 21 analytes. Participants were clinically assessed at baseline and follow-up and classified according to a validated staging model. Data were used to assess associations with clinical stability over a 12-month follow-up period. IL-17A was increased in transitioning patients (uncorrected p = 0.045; adjusted p = 0.64 after correction for multiple comparisons). A logistic regression model combining IL-17A, IFN-γ and MIP-3α discriminated between groups with an AUC of 0.853 in this exploratory cohort. These findings highlight the potential relevance of neuroimmune mechanisms in the development of psychotic disorders and suggest that immunological markers may merit further consideration within staging-based models of care, pending external validation. Incorporating cytokine profiling into clinical practice may potentially inform personalized treatment strategies and lead to better long-term outcomes for individuals with FEP.